Clinical trials: Cell Transplantation
Newly Diagnosed Multiple Myeloma
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant.
- Trial name
- IsaIberVD (NCT07601100)
- Testing
- Isatuximab, Iberdomide, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Neutropenia
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.
- Trial name
- NCT00005787
- Testing
- epoetin alfa, filgrastim, recombinant flt3 ligand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Parkinson Disease (PD)
Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease
Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells…
- Trial name
- NCT07572071
- Testing
- Dopacell, Immunosuppressive Regimen, Customized microinjection device
- Where
- 3 sites in Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem…
- Trial name
- NCT01564563
- Testing
- standard therapy, activated recombinant human factor VII
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Transplant Failure
T-lymphocytes CD8+/HLA-DR+ and Acute Rejection After Lung Transplantation
The objectives of the study is to identify associations between acute rejection and the increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of activation and differentiation (HLA-DR, CD25, CD38…
- Trial name
- NCT03587493
- Testing
- BLOOD SAMPLE ANALYSIS
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Amyotrophic Lateral Sclerosis
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
The study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal derived neural stem cell transplantation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01730716
- Testing
- Human spinal cord stem cell implantation
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuralstem Inc.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00005852
- Testing
- anti-thymocyte globulin, filgrastim, muromonab-CD3
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
- Trial name
- ICT-HCT (NCT01812252)
- Testing
- Azacitidine (AZC), Decitabine, Quality-of-Life Assessment
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed Adult AML, Refractory AML
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy…
- Conditions
- Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
- Trial name
- NCT07591649
- Testing
- AdaptNK, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Limbal Stem Cell Deficiency
Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial
This project aims to conduct a multicentre human clinical trial to effectively diagnose and treat limbal stem cell deficiency (LSCD) which can be caused by a number of different disease processes, all of which have a common…
- Trial name
- MLEC (NCT02318485)
- Testing
- Limbal epithelial stem cell graft
- Where
- 3 sites in Belgium
- Volunteers
- 27 people
- Sponsor
- University Hospital, Antwerp
Hematologic Malignancies
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
The purpose of this study is to develop a way of treating patients who do not have a completely matched family donor or a readily available unrelated donor with bone marrow transplant by using a partially-matched family donor.
- Trial name
- NCT00429143
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoid Leukemia, Acute, Myeloid Malignancy
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT).
- Conditions
- Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
- Trial name
- NCT05350163
- Testing
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Guenther Koehne
Central Nervous System Neoplasms, Neoplasm Metastasis
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts.
- Trial name
- CN-306 (NCT00629187)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tufts Medical Center
Other Cancer
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).
- Trial name
- NCT03674047
- Testing
- ruxolitinib
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM) patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT) followed by maintenance therapy with MEDI-551.
- Trial name
- NCT03218163
- Testing
- MEDI-551 Maintenance
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
The purpose of this prospective, open-label, randomized multicenter study is to evaluate the safety and efficacy of low dose decitabine in combination with modified BUCY vs modified BUCY as a myeloablative conditioning regimen…
- Conditions
- Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT03256071
- Testing
- Decitabine plus Modified BUCY, Modified BUCY
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital of Soochow University
MDS, CMML
Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML
Stem cell transplantation and blood product transfusions are standard of care for Myelodysplastic Syndromes (MDS). Several studies have shown changes in serum ferritin and non-transferrin-bound iron (NTBI) in patients undergoing…
- Trial name
- NCT06267898
- Where
- 6 sites in Belgium, Czechia and 1 more
- Volunteers
- 222 people
- Sponsor
- European Society for Blood and Marrow Transplantation
End-Stage Renal Disease, Kidney Failure
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
T regulatory cells (T regs) are responsible for immune tolerance in solid organ transplant patients. This study will evaluate the treatment of children with kidney transplants either with Campath and other immune system…
- Trial name
- NCT01446484
- Testing
- CD4+CD25+CD127lowFoxP3+ T regulatory cells injection, Alemtuzumab, Mycophenolate mofetil
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Pirogov Russian National Research Medical University
Acute Graft-versus-host Disease
Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Despite significant progress in overall survival and event-free survival in Pediatric Hematopoietic Stem Cell Transplant (HSCT), therapeutic options for graft-versus-host disease control remain limited, particularly in…
- Trial name
- NCT05825833
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- IRCCS Burlo Garofolo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.